S. Fucile

Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON).

C. Gessner, R. V. van Zyl-Smit, J. Maspero, 2020, Respiratory medicine.

Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study

J. Wedzicha, C. Jenkins, Dave Singh, 2019, Respiratory Research.

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD

A. Anzueto, C. Vogelmeier, K. Kostikas, 2017, International journal of chronic obstructive pulmonary disease.

Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety

D. Price, M. Castro, A. Bourdin, 2020, European Respiratory Review.

Indacaterol/glycopyrronium (IND/GLY) improves lung function irrespective of gender baseline differences in patients with COPD: A pooled analysis from the IGNITE Program

K. Kostikas, R. Fogel, S. Fucile, 2016 .

Bronquitis plástica asociada a miocardiopatía restrictiva

S. Fucile, A. Teper, Romina Pascale, 2004 .

Response to Indacaterol/Glycopyrronium (IND/GLY) by Sex in Patients with COPD: A Pooled Analysis from the IGNITE Program

K. Kostikas, R. Fogel, S. Fucile, 2017, COPD.